Related Experiment Video
Updated: Jul 16, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody
1University of Utah, Huntsman Cancer Institute, Room 3243, 2000 Circle of Hope Drive, Salt Lake City, UT 84112, USA. scott.kuwada@hsc.utah.edu
Abstract:
PDL Biopharma Inc (formerly Eos Biotechnology Inc) and Biogen Idec Inc are developing volociximab, an angiogenesis-inhibiting chimeric mAb that targets AAB1, a component protein of alpha5/beta1 integrin, for the potential treatment of solid tumors, including renal cell carcinoma. Two phase II clinical trials evaluating volociximab in solid tumors are underway. Volociximab is also under investigation for the treatment of age-related macular degeneration.
Related Concept Videos
Mechanism of Angiogenesis
Regulation of Angiogenesis and Blood Supply

